Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Cell Physiol ; 227(5): 2069-78, 2012 May.
Article in English | MEDLINE | ID: mdl-21769863

ABSTRACT

p21(CIP) is a potent cell cycle inhibitor often up-regulated in differentiation. Protooncogene MYC induces cell growth and proliferation, inhibits differentiation and represses p21(CIP). However, both molecules are involved in processes of polyploidisation, cell size increase, differentiation and senescence. It is unclear why MYC has a dual role in differentiation. We have previously shown that overexpression of p21(CIP) in K562 myeloid cells induces megakaryocytic differentiation with polyploidy. We have now investigated the requirements for p21(CIP) to block mitosis and induce differentiation in the presence of overactivated MYC. Silencing and over-expression studies showed that p21(CIP) is required to induce differentiation. However, the expression of p21(CIP) needs to be transient to irreversibly inhibit mitosis but not DNA replication, what leads to polyploidy. Transient overexpression of p21(CIP) caused early down-regulation of mitotic Cyclins and up-regulation of G1/S Cyclins D and E, changes typical of endoreplication. Interestingly, over-activation of MYC did not release the proliferative block imposed by p21(CIP) and instead, accelerated cell size increase, megakaryocytic differentiation and polyploidisation. Our data suggests that in some systems p21(CIP) takes part in a mitosis control driving MYC-induced cellular growth into differentiation.


Subject(s)
Cell Differentiation/physiology , Cyclin-Dependent Kinase Inhibitor p21/metabolism , K562 Cells , Megakaryocytes/physiology , Mitosis/physiology , Proto-Oncogene Proteins c-myc/metabolism , Cyclin-Dependent Kinase Inhibitor p21/genetics , Cyclins/genetics , Cyclins/metabolism , Humans , Megakaryocytes/cytology , Polyploidy , Proto-Oncogene Proteins c-myc/genetics , Zinc/metabolism
2.
Mol Cancer Ther ; 5(5): 1166-75, 2006 May.
Article in English | MEDLINE | ID: mdl-16731748

ABSTRACT

2,4,6-Triiodophenol (Bobel-24, AM-24) was originally described as a nonsteroid antiinflammatory molecule. We have synthesized three derivatives of Bobel-24 (Bobel-4, Bobel-16, and Bobel-30) and tested their activities as putative antileukemic agents. We have found that Bobel-24 and Bobel-16 were dual inhibitors of cyclooxygenase and 5-lipoxygenase, whereas Bobel-4 and Bobel-30 were selective against 5-lipoxygenase. We have tested the antiproliferative activity of these compounds on a panel of cell lines derived from myeloid and lymphoid leukemias (K562, Raji, HL-60, and Molt4). The cytotoxic IC(50) in these cell lines ranged between 14 and 50 micromol/L, but it was higher for nontransformed cells such as 32D, NIH3T3, or human leukocytes. All compounds showed cytotoxic activity on all tested cell lines, accompanied by DNA synthesis inhibition and arrest in the G(0)/G(1) phase. Bobel-16, Bobel-4, and Bobel-24 induced a caspase-independent cell death in K562 and Raji cells, accompanied by chromatin condensation, cytochrome c release, and dissipation of mitochondrial membrane potential in a concentration-dependent manner and production of reactive oxygen species. As the proto-oncogene MYC is involved in mitochondrial biogenesis and survival of leukemia cells, we tested its effect on bobel activity. Bobel-24 induced down-regulation of MYC in K562 and, consistently, ectopic expression of MYC results in partial protection towards the cytotoxic effect of Bobel-24. In conclusion, Bobel derivatives induce a caspase- and Bcl-2-independent cell death in which mitochondrial permeabilization and MYC down-regulation are involved. Bobels may serve as prototypes for the development of new agents for the therapy of leukemia.


Subject(s)
Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Leukemia/metabolism , Mitochondria/drug effects , Phenols/chemistry , Phenols/pharmacology , Proto-Oncogene Proteins c-myc/antagonists & inhibitors , Animals , Antineoplastic Agents/chemical synthesis , Apoptosis/drug effects , Arachidonate 5-Lipoxygenase/metabolism , Biphenyl Compounds/chemical synthesis , Biphenyl Compounds/chemistry , Biphenyl Compounds/pharmacology , Caspases/metabolism , Cell Cycle/drug effects , Cell Membrane Permeability/drug effects , Cyclooxygenase 2 Inhibitors/metabolism , Cyclooxygenase 2 Inhibitors/pharmacology , Dose-Response Relationship, Drug , Down-Regulation/drug effects , HL-60 Cells , Humans , K562 Cells , Lipoxygenase Inhibitors , Mice , Mitochondria/metabolism , NIH 3T3 Cells , Phenols/chemical synthesis , Prostaglandin-Endoperoxide Synthases/metabolism , Proto-Oncogene Mas , Proto-Oncogene Proteins c-myc/metabolism , Reactive Oxygen Species/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...